Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: A morphologic and immunohistochemical analysis of 37 cases

American Journal of Surgical Pathology

Volumn 38, Issue 6, 2014, Pages 743-755

  Maniar, Kruti P ^a   Wang, Yihong ^a   Visvanathan, Kala ^a   Shih, Ie Ming ^a,b   Kurman, Robert J ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Atypical proliferative serous tumors; Lymph node involvement; Microinvasion; Serous borderline tumors

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER STAGING; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TUMOR INVASION; YOUNG ADULT;

ADULT; AGED; APOPTOSIS; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 84900789797     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000155     Document Type: Article

References (34)

1. Tavassoli FA. Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion). Mod Pathol. 1988;1:407-414
2. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: A report of 21 cases. Hum Pathol. 1990;21: 397-403
3. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539-557
4. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer. 1988;62:2212-2222
5. Silverberg SG, Bell DA, Kurman RJ, et al. Borderline ovarian tumors: Key points and workshop summary. Hum Pathol. 2004; 35:910-917
6. Seidman JD, Soslow RA, Vang R, et al. Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol. 2004;35:918-933
7. McKenney JK, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): A reevaluation of the concept of stromal microinvasion. Am J Surg Pathol. 2006;30:1209-1221
8. Nayar R, Siriaunkgul S, Robbins KM, et al. Microinvasion in low malignant potential tumors of the ovary. Hum Pathol. 1996;27: 521-527
9. Silva EG, Kurman RJ, Russell P, et al. Symposium: Ovarian tumors of borderline malignancy. Int J Gynecol Pathol. 1996;15:281-302
10. Remmele W, Hildebrand U, Hienz HA, et al. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1986;409:127-147
11. Schlosshauer PW, Deligdisch L, Penault-Llorca F, et al. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Int J Gynecol Pathol. 2011;30:22-29
12. Friedrich M, Villena-Heinsen C, Reitnauer K, et al. Malignancies of the uterine corpus and immunoreactivity score of the DNA "mismatch-repair" enzyme human Mut-S-homologon-2. J Histochem Cytochem. 1999;47:113-118
13. Leers MPG, Kölgen W, Björklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187:567-572
14. Brown GW, Mood AM. On Median Tests for Linear Hypothesis. In: Neyman J, ed. Proceedings of the Second Berkeley Symposium on Mathematical Statistics and Probability. Berkeley and Los Angeles: University of California Press; 1951:159-166
15. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol. 1996;20:1331-1345
16. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors) A long-Term followup study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer. 1996;78:278-286
17. Casey AC, Bell DA, Lage JM, et al. Epithelial ovarian tumors of borderline malignancy: Long-Term follow-up. Gynecol Oncol. 1993;50:316-322
18. Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol. 2003;14:592-598
19. Sangoi AR, McKenney JK, Dadras SS, et al. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: A case control study. Am J Surg Pathol. 2008;32:261-268
20. Hyun TS, Barnes M, Tabatabai ZL. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology. Acta Cytol. 2012;56:527-532
21. Katzenstein AL, Mazur MT, Morgan TE, et al. Proliferative serous tumors of the ovary. Histologic features and prognosis. Am J Surg Pathol. 1978;2:339-355
22. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): Pathology, prognosis, and proposed classification. Am J Surg Pathol. 2006;30:614-624
23. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): Outcomebased study of 276 patients with long-Term (or =5-year) followup. Am J Surg Pathol. 2005;29:707-723
24. Leake JF, Rader JS, Woodruff JD, et al. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol. 1991;42:124-130
25. Lesieur B, Kane A, Duvillard P, et al. Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol. 2011;204:438.e431-438.e437
26. Camatte S, Morice P, Atallah D, et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: An analysis of a series of 42 lymphadenectomies. J Am Coll Surg. 2002;195:332-338
27. Buttin BM, Herzog TJ, Powell MA, et al. Epithelial ovarian tumors of low malignant potential: The role of microinvasion. Obstet Gynecol. 2002;99:11-17
28. Fadare O, Orejudos MP, Jain R, et al A comparative analysis of lymphatic vessel density in ovarian serous tumors of low malignant potential (borderline tumors) with and without lymph node involvement. Int J Gynecol Pathol. 2008;27:483-490
29. Moore WF, Bentley RC, Berchuck A, et al. Some mullerian inclusion cysts in lymph nodes may sometimes be metastases from serous borderline tumors of the ovary. Am J Surg Pathol. 2000;24:710-718
30. Tan LK, Flynn SD, Carcangiu ML. Ovarian serous borderline tumors with lymph node involvement. Clinicopathologic and DNA content study of seven cases and review of the literature. Am J Surg Pathol. 1994;18:904-912
31. Bell DA, Scully RE. Clinicopathologic features of lymph node (LN) involvement with ovarian serous borderline tumors (OSBT). Mod Pathol. 1992;5:61A
32. Shiraki M, Otis CN, Donovan JT, et al. Ovarian serous borderline epithelial tumors with multiple retroperitoneal nodal involvement: Metastasis or malignant transformation of epithelial glandular inclusions?. Gynecol Oncol. 1992;46:255-258
33. Kadar N, Krumerman M. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor). Gynecol Oncol. 1995;59: 394-397
34. Prade M, Spatz A, Bentley R, et al. Borderline and malignant serous tumor arising in pelvic lymph nodes: Evidence of origin in benign glandular inclusions. Int J Gynecol Pathol. 1995;14:87-91.